ScholarIQanswers from OpenAlex
Texas Oncology
InstitutionResearch output, impact & collaborations
Texas Oncology is a institution indexed in ScholarIQ from OpenAlex.
What is known about Texas Oncology?
ScholarIQrecord summary
Texas Oncology is a research organisation in Oklahoma City, US. OpenAlex records 4,962 works and 661,816 citations for it. 1,091 researchers list it as their most recent affiliation.
How many works does Texas Oncology have?
ScholarIQindexed works
Texas Oncology has 4,962 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Texas Oncology have?
ScholarIQcitation count
Texas Oncology has 661,816 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Texas Oncology?
ScholarIQresearcher count
Texas Oncology has 1,091 researchers in the ScholarIQ index.
What is the average h-index at Texas Oncology?
ScholarIQavg h-index
Texas Oncology has an average h-index of 65.2 in OpenAlex.
What is the ROR of Texas Oncology?
ScholarIQror
The ROR for Texas Oncology is on the source record.
What is the OpenAlex record for Texas Oncology?
ScholarIQopenalex
The OpenAlex for Texas Oncology is on the source record.
What is the Wikidata of Texas Oncology?
ScholarIQwikidata
The Wikidata for Texas Oncology is on the source record.
Who are the most-cited researchers behind Texas Oncology?
ScholarIQtop researchers by citations
What are the most-cited papers on Texas Oncology?
ScholarIQmost cited works
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Pedro T. Ramírez, Michael Frumovitz, René Pareja, Aldo López, Marcelo de Andrade Vieira, Reitan Ribeiro, Alessandro Buda, Xiaojian Yan, Yao Shuzhong, Naven Chetty, David Isla, Mariano Tamura, Tao Zhu, Kristy Robledo, Val Gebski, Rebecca Asher, Vanessa Behan, James Nicklin, Robert L. Coleman, Andreas Obermair
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Méndez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, Syed Zafar, Stephanie Snow, Andrew H. Ko, Kynan Feeney, Michael Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, Ming Lei, Prianka Singh, Kaoru Kondo, James M. Cleary, Markus Moehler
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D. Gelber, Sébastien Guillaume, A. Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, José Baselga, Manfred Kaufmann, David Cameron, Richard H. Bell, Jonas Bergh, Robert L. Coleman, Andrew Wardley, Nadia Harbeck, R.I. Lopez, Peter Mallmann, Karen A. Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez‐Rovira, Martine Piccart
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Premal H. Thaker, Liz Y. Han, Aparna A. Kamat, Jesusa M.G. Arevalo, Rie Takahashi, Chunhua Lu, Nicholas B. Jennings, Guillermo N. Armaiz-Peña, James A. Bankson, Murali Ravoori, William M. Merritt, Yvonne G. Lin, Lingegowda S. Mangala, Tae Jin Kim, Robert L. Coleman, Charles N. Landen, Yang Li, Edward Felix, Ángela Sanguino, Robert A. Newman, Mary Lloyd, David M. Gershenson, Vikas Kundra, Gabriel Lopez‐Berestein, Susan K. Lutgendorf, Steve W. Cole, Anil K. Sood
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish
How much of the research on Texas Oncology is open access?
ScholarIQopen access share
67%OPEN ACCESS